Developer docs
API playgroundTry for free, no card

Search company profiles

QurAlis

Full company profile

uuid0000b6a

Namestring
QurAlis
Legal namestring
QurAlis Corporation
Websiteurl
quralis.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

QurAlis is a clinical-stage biotechnology company founded in December 2016 in Cambridge, Massachusetts, by Harvard neuroscientists Kasper Roet, Kevin Eggan, and Clifford Woolf alongside Q-State Biosciences. The company develops precision antisense oligonucleotide (ASO) medicines targeting genetically and clinically defined patient subpopulations within amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Fragile X syndrome, and other neurodegenerative and neurological diseases. QurAlis was the first to demonstrate that motor neurons derived from ALS patients via iPSC technology can be used to model disease and identify therapeutic targets, and operates a proprietary platform called FlexASO® Splice Modulator for generating splice-switching ASOs with improved potency, therapeutic index, and biodistribution. Its clinical pipeline comprises QRL-201 (first-in-class STATHMIN-2 restoring ASO for sporadic ALS, currently in Phase 2 ANQUR with up to 50% decrease in disease progression reported), QRL-101 (selective Kv7.2/7.3 ion channel opener for ALS hyperexcitability, Phase 1 with target engagement confirmed), and QRL-204 (UNC13A splice-correcting ASO for ALS/FTD, exclusively licensed to Eli Lilly).

The company is pre-revenue from a product sales perspective. Its revenue model is built on venture capital financing ($42M Series A in 2020, $88M Series B in 2023) supplemented by licensing and milestone payments from pharmaceutical partners — most notably the $45M upfront plus up to $577M in potential milestones from Eli Lilly for QRL-204. QurAlis has secured Clinical Trial Authorizations across Health Canada, the EU, and the UK, and operates a global clinical network spanning 11+ academic medical centers. Its go-to-market model is a traditional clinical-development-to-commercialization pathway: advance therapies through Phase 1/2/3 trials, secure regulatory approvals, then commercialize via specialty pharmacy and hospital distribution channels. The company recently doubled its physical footprint with a new 30,000 sq ft global headquarters and operates a Leiden, Netherlands European R&D and manufacturing facility, with leadership drawn from firms including Karuna Therapeutics (acquired by BMS for $14B), AbbVie, Retrophin/Pfizer, and Wave Life Sciences.

Short descriptiontext

QurAlis is a clinical-stage biotechnology company developing precision antisense oligonucleotide therapies for ALS, frontotemporal dementia, Fragile X syndrome, and other neurodegenerative diseases using its proprietary FlexASO® Splice Modulator Platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antisense oligonucleotide therapeutics, precision medicine ALS, neurodegenerative disease therapeutics, splice modulating ASOs, clinical stage biotechnology
Industry4 codes
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
ALS and Neurodegenerative Disease Precision Medicine
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Biopharmaceutical Development and Commercialization
TypeLicensing Royalties
Description

As a clinical-stage biotechnology company, QurAlis generates no current revenue. The company is funded through equity financing (Series A and Series B venture funding) and licensing/partnership agreements. Future revenue will be generated through the commercialization of proprietary therapeutic candidates upon regulatory approval, through direct sales or licensing arrangements.

quralis.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

QurAlis has entered into an exclusive worldwide license agreement with Eli Lilly for QRL-204 (UNC13A-targeting ASO), receiving an upfront payment of $45 million plus equity investment, and is eligible for future milestone payments of up to $577 million and tiered royalties on net sales.

quralis.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1FlexASO®
Description

Proprietary Anti-Sense Oligonucleotide Splice Modulator Platform developed to generate splice-switching ASOs with improved potency, increased therapeutic index and improved bio-distribution

quralis.com
Core offering1 text field

QurAlis is a clinical-stage biotechnology company developing precision antisense oligonucleotide (ASO) medicines that target defined genetic and molecular drivers of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Its wholly owned lead candidates are QRL-201 (first-in-class STATHMIN-2 restoring ASO for sporadic ALS, in Phase 1/2 ANQUR) and QRL-101 (selective Kv7.2/7.3 ion channel opener for ALS and epilepsy, in Phase 1). Its UNC13A asset QRL-204 has been out-licensed to Eli Lilly. All candidates are generated through the proprietary FlexASO® Splice Modulator Platform, which QurAlis also leverages for collaborations such as UMass Chan's Fragile X syndrome program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Up to 50% decrease in disease progression in ALS patients treated with QRL-201 vs. placebo, measured by ALSFRS-R score, across 69 patients in Phase 1/2 ANQUR trial
+6 more records
Product overview1 text field

QurAlis is a clinical-stage biotechnology company and leader in developing precision therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's portfolio includes therapeutic candidates QRL-201 (first-in-class STATHMIN-2 restoring ASO for sporadic ALS) and QRL-101 (best-in-class Kv7.2/7.3 ion channel opener for ALS and epilepsy), both in clinical development. QRL-204 (UNC13A-restoring therapy) has been licensed to Eli Lilly. The FlexASO® proprietary platform enables development of splice-switching antisense oligonucleotides with improved potency and therapeutic index. The company is also advancing programs in frontotemporal dementia (FTD), Fragile X syndrome, and other neurological conditions.

Product and service3 records
1QRL-201
CategoryTherapeutic candidate (antisense oligonucleotide for ALS)
Description

First-in-class antisense oligonucleotide precision medicine that restores STATHMIN-2 (STMN2) expression in patients with sporadic ALS, intended as a disease-modifying therapy targeting TDP-43-related loss of STMN2 in motor neurons. It is being evaluated in the ANQUR Phase 1/2 clinical trial (NCT05633459) for ALS patients.

2QRL-101
CategoryTherapeutic candidate (selective Kv7.2/7.3 ion channel opener for ALS / epilepsy / pain)
Description

Potentially best-in-class selective Kv7.2/7.3 ion channel opener, an antisense/small-molecule-acting precision therapy intended to treat hyperexcitability-induced disease progression in ALS and is also being explored in epilepsy and pain. The Phase 1 program in ALS patients reported target engagement signals and EEG spectral power changes in beta and gamma bands.

3QRL-204
CategoryTherapeutic candidate (licensed antisense oligonucleotide for ALS and FTD)
Description

Potentially first-in-class splice-switching antisense oligonucleotide designed to restore UNC13A function in ALS and FTD by correcting TDP-43-driven UNC13A pre-mRNA mis-splicing; out-licensed exclusively worldwide to Eli Lilly and Company for development and commercialization.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeOthersAnnounced on2025-06-18
Description

Healthpeak Properties, QurAlis' landlord at 35 Cambridgepark Drive, developed and built out QurAlis' 30,000 square foot global headquarters facility including lab and office space. Healthpeak is a life science real estate company providing Class A lab space in Cambridge's Alewife Biotech Park.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-06-03
Description

QurAlis granted Eli Lilly an exclusive worldwide license to develop and commercialize QRL-204 and other UNC13A-targeting ASO compounds for ALS, FTD, and other neurodegenerative diseases. QurAlis received $45 million upfront plus equity investment and is eligible for up to $577 million in future milestone payments plus tiered royalties on net sales. The agreement includes an R&D collaboration to identify and develop additional UNC13A-targeting candidates using QurAlis' FlexASO Platform. UNC13A mis-splicing occurs in up to 63% of ALS patients and up to one-third of FTD cases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-15
Description

QurAlis entered into an exclusive license agreement with UMass Chan Medical School on a novel RNA-targeted mechanism to restore functional protein for Fragile X syndrome (FXS). The collaboration with Dr. Joel Richter's lab confirmed FMR1-217 as a target for up to 80% of FXS patients, leveraging QurAlis' FlexASO platform for splice correction. Preliminary data suggest feasibility of a biomarker to detect mis-splicing of FMR1 in FXS patients.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-05-15
Description

QurAlis and Quiver Bioscience entered into a research collaboration to advance a novel gene-targeted therapeutic approach for Fragile X syndrome. The collaboration combines Quiver's Genomic Positioning System (GPS) drug discovery platform with QurAlis' ASO development expertise to build a data package for advancing FXS therapeutics.

5Patient Organizations (ALS Association, Project ALS, Target ALS, NEALS, I AM ALS, ALS Foundation, and others)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-06-27
Description

QurAlis maintains partnerships with multiple ALS patient organizations to support clinical trial recruitment, patient engagement, and awareness. These organizations include ALS Association, ALS Foundation, Project ALS, Target ALS, NEALS, I AM ALS, and others. These partnerships facilitate patient-centered drug development and community outreach.

quralis.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

QurAlis signed a deal with Eli Lilly in 2020 focused on Kv7.2/7.3 dysfunction in ALS, which built on QurAlis' foundational science showing that Kv7.2/7.3 dysfunction drives toxic hyperexcitability-induced neurodegeneration in ALS. This partnership contributed to the development of QRL-101.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Category-defining antisense oligonucleotide therapeutics company and the most direct competitor to QurAlis. Ionis developed Spinraza (nusinersen) for SMA and tofersen for SOD1 ALS, and operates a broad CNS ASO pipeline that directly overlaps with QurAlis' FlexASO platform approach. Its proven track record in ASO development and CNS delivery is the benchmark QurAlis is measured against.

TypeBroad incumbent
Description

Large biopharmaceutical company commercializing tofersen (with Ionis) for SOD1 ALS and the broader Spinraza SMA franchise. Biogen is the dominant commercial incumbent in ALS therapeutics and represents the standard-of-care competitor QurAlis would face at launch, with far greater commercial infrastructure and reimbursement leverage.

TypeDirect peer
Description

Clinical-stage RNA therapeutics company with a stereopure ASO platform targeting neurological diseases including ALS and Huntington's disease. Wave's PRISM platform overlaps directly with QurAlis' FlexASO chemistry approach, and its CTO Hagen Cramer's prior leadership at Wave makes it a particularly close technology analog.

TypeDirect peer
Description

Clinical-stage biotechnology company developing antisense oligonucleotide medicines that increase protein expression via RNA splicing modulation for genetic diseases, including CNS disorders such as Dravet syndrome and ADOA. Direct platform analog to QurAlis' FlexASO splice-modulator approach in the rare neurological disease space.

TypeEmerging player
Description

Clinical-stage RNA editing company developing Axiomer® platform-based therapies for genetic diseases including CNS and ophthalmology indications. Overlaps with QurAlis in RNA-targeted therapeutic modalities and rare neurological disease focus, though using an editing rather than splice-modulating mechanism.

TypeBroad incumbent
Description

Established RNA interference (siRNA) therapeutics leader with multiple approved products and an active CNS pipeline (e.g., for Huntington's disease). Competes with QurAlis in the broader RNA therapeutics space for capital, partnerships, and physician attention, though Alnylam's siRNA modality differs from QurAlis' ASO approach.

TypeDirect peer
Description

Clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases including ALS, Parkinson's, and Hunter syndrome. Denali is one of the most advanced and well-capitalized private competitors in the neurodegenerative precision-medicine space, directly competing for partnerships and ALS market positioning.

TypeEmerging player
Description

Neuroscience-focused clinical-stage biotech acquired by Bristol-Myers Squibb for $14 billion in 2024 for its schizophrenia therapy. Karuna is a directly relevant precedent for QurAlis' exit trajectory given the shared CFO background (Jason Brown) and the demonstrated large-pharma appetite for CNS-focused clinical-stage biotechs.

TypeEmerging player
Description

Clinical-stage neuroscience company developing CNS therapies (Zulresso, Zurzuvae) with overlapping neuroscience drug development infrastructure and investor base. Comparable in clinical-stage neuroscience focus and indication-overlap (epilepsy is one of QurAlis' expansion areas).

TypeEmerging player
Description

Clinical-stage RNA therapeutics company with multiple modalities including siRNA and ASO-like trigger designs targeting liver and CNS diseases. Comparable as a private/public RNA therapeutics competitor with active neurology pipeline programs and broad platform ambitions similar to QurAlis' FlexASO strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

QurAlis

ALS and Neurodegenerative Disease Precision Medicinequralis.com

QurAlis is a clinical-stage biotechnology company developing precision antisense oligonucleotide therapies for ALS, frontotemporal dementia, Fragile X syndrome, and other neurodegenerative diseases using its proprietary FlexASO® Splice Modulator Platform.

What QurAlis does

QurAlis is a clinical-stage biotechnology company founded in December 2016 in Cambridge, Massachusetts, by Harvard neuroscientists Kasper Roet, Kevin Eggan, and Clifford Woolf alongside Q-State Biosciences. The company develops precision antisense oligonucleotide (ASO) medicines targeting genetically and clinically defined patient subpopulations within amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Fragile X syndrome, and other neurodegenerative and neurological diseases. QurAlis was the first to demonstrate that motor neurons derived from ALS patients via iPSC technology can be used to model disease and identify therapeutic targets, and operates a proprietary platform called FlexASO® Splice Modulator for generating splice-switching ASOs with improved potency, therapeutic index, and biodistribution. Its clinical pipeline comprises QRL-201 (first-in-class STATHMIN-2 restoring ASO for sporadic ALS, currently in Phase 2 ANQUR with up to 50% decrease in disease progression reported), QRL-101 (selective Kv7.2/7.3 ion channel opener for ALS hyperexcitability, Phase 1 with target engagement confirmed), and QRL-204 (UNC13A splice-correcting ASO for ALS/FTD, exclusively licensed to Eli Lilly).

The company is pre-revenue from a product sales perspective. Its revenue model is built on venture capital financing ($42M Series A in 2020, $88M Series B in 2023) supplemented by licensing and milestone payments from pharmaceutical partners — most notably the $45M upfront plus up to $577M in potential milestones from Eli Lilly for QRL-204. QurAlis has secured Clinical Trial Authorizations across Health Canada, the EU, and the UK, and operates a global clinical network spanning 11+ academic medical centers. Its go-to-market model is a traditional clinical-development-to-commercialization pathway: advance therapies through Phase 1/2/3 trials, secure regulatory approvals, then commercialize via specialty pharmacy and hospital distribution channels. The company recently doubled its physical footprint with a new 30,000 sq ft global headquarters and operates a Leiden, Netherlands European R&D and manufacturing facility, with leadership drawn from firms including Karuna Therapeutics (acquired by BMS for $14B), AbbVie, Retrophin/Pfizer, and Wave Life Sciences.

QurAlis firmographics

Firmographics
Name
QurAlis
Legal name
QurAlis Corporation
Website
https://quralis.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
QurAlis is a clinical-stage biotechnology company developing precision antisense oligonucleotide therapies for ALS, frontotemporal dementia, Fragile X syndrome, and other neurodegenerative diseases using its proprietary FlexASO® Splice Modulator Platform.
Ownership category
akta.pro rank

QurAlis industry classification

Industry
Product category
ALS and Neurodegenerative Disease Precision Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Antisense oligonucleotide therapeutics
  • Precision medicine ALS
  • Neurodegenerative disease therapeutics
  • Splice modulating ASOs
  • Clinical stage biotechnology

Where QurAlis is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices3 records

Markets served

QurAlis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biopharmaceutical Development and Commercialization: As a clinical-stage biotechnology company, QurAlis generates no current revenue. The company is funded through equity financing (Series A and Series B venture funding) and licensing/partnership agreements. Future revenue will be generated through the commercialization of proprietary therapeutic candidates upon regulatory approval, through direct sales or licensing arrangements.
  2. Licensing and Milestone Payments: QurAlis has entered into an exclusive worldwide license agreement with Eli Lilly for QRL-204 (UNC13A-targeting ASO), receiving an upfront payment of $45 million plus equity investment, and is eligible for future milestone payments of up to $577 million and tiered royalties on net sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

QurAlis product offering

Product offering

Core offering

QurAlis is a clinical-stage biotechnology company developing precision antisense oligonucleotide (ASO) medicines that target defined genetic and molecular drivers of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Its wholly owned lead candidates are QRL-201 (first-in-class STATHMIN-2 restoring ASO for sporadic ALS, in Phase 1/2 ANQUR) and QRL-101 (selective Kv7.2/7.3 ion channel opener for ALS and epilepsy, in Phase 1). Its UNC13A asset QRL-204 has been out-licensed to Eli Lilly. All candidates are generated through the proprietary FlexASO® Splice Modulator Platform, which QurAlis also leverages for collaborations such as UMass Chan's Fragile X syndrome program.

Product overview

QurAlis is a clinical-stage biotechnology company and leader in developing precision therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's portfolio includes therapeutic candidates QRL-201 (first-in-class STATHMIN-2 restoring ASO for sporadic ALS) and QRL-101 (best-in-class Kv7.2/7.3 ion channel opener for ALS and epilepsy), both in clinical development. QRL-204 (UNC13A-restoring therapy) has been licensed to Eli Lilly. The FlexASO® proprietary platform enables development of splice-switching antisense oligonucleotides with improved potency and therapeutic index. The company is also advancing programs in frontotemporal dementia (FTD), Fragile X syndrome, and other neurological conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • FlexASO®: Proprietary Anti-Sense Oligonucleotide Splice Modulator Platform developed to generate splice-switching ASOs with improved potency, increased therapeutic index and improved bio-distribution

Products and services

  • QRL-201 First-in-class antisense oligonucleotide precision medicine that restores STATHMIN-2 (STMN2) expression in patients with sporadic ALS, intended as a disease-modifying therapy targeting TDP-43-related loss of STMN2 in motor neurons. It is being evaluated in the ANQUR Phase 1/2 clinical trial (NCT05633459) for ALS patients.
  • QRL-101 Potentially best-in-class selective Kv7.2/7.3 ion channel opener, an antisense/small-molecule-acting precision therapy intended to treat hyperexcitability-induced disease progression in ALS and is also being explored in epilepsy and pain. The Phase 1 program in ALS patients reported target engagement signals and EEG spectral power changes in beta and gamma bands.
  • QRL-204 Potentially first-in-class splice-switching antisense oligonucleotide designed to restore UNC13A function in ALS and FTD by correcting TDP-43-driven UNC13A pre-mRNA mis-splicing; out-licensed exclusively worldwide to Eli Lilly and Company for development and commercialization.

Quantifiable outcome

  • Up to 50% decrease in disease progression in ALS patients treated with QRL-201 vs. placebo, measured by ALSFRS-R score, across 69 patients in Phase 1/2 ANQUR trial
  • +6 more outcomes

Companies that use QurAlis

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles3 records

QurAlis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

QurAlis partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor, flagship and core.

  • Healthpeak PropertiesminorOthers · 18 June 2025Healthpeak Properties, QurAlis' landlord at 35 Cambridgepark Drive, developed and built out QurAlis' 30,000 square foot global headquarters facility including lab and office space. Healthpeak is a life science real estate company providing Class A lab space in Cambridge's Alewife Biotech Park.
  • Eli Lilly and CompanyflagshipOEM/ Whitelabel/ Licensing Partner · 3 June 2024QurAlis granted Eli Lilly an exclusive worldwide license to develop and commercialize QRL-204 and other UNC13A-targeting ASO compounds for ALS, FTD, and other neurodegenerative diseases. QurAlis received $45 million upfront plus equity investment and is eligible for up to $577 million in future milestone payments plus tiered royalties on net sales. The agreement includes an R&D collaboration to identify and develop additional UNC13A-targeting candidates using QurAlis' FlexASO Platform. UNC13A mis-splicing occurs in up to 63% of ALS patients and up to one-third of FTD cases.
  • UMass Chan Medical SchoolcoreStrategic or Co-development Partner · 15 May 2024QurAlis entered into an exclusive license agreement with UMass Chan Medical School on a novel RNA-targeted mechanism to restore functional protein for Fragile X syndrome (FXS). The collaboration with Dr. Joel Richter's lab confirmed FMR1-217 as a target for up to 80% of FXS patients, leveraging QurAlis' FlexASO platform for splice correction. Preliminary data suggest feasibility of a biomarker to detect mis-splicing of FMR1 in FXS patients.
  • Quiver BioscienceminorStrategic or Co-development Partner · 15 May 2024QurAlis and Quiver Bioscience entered into a research collaboration to advance a novel gene-targeted therapeutic approach for Fragile X syndrome. The collaboration combines Quiver's Genomic Positioning System (GPS) drug discovery platform with QurAlis' ASO development expertise to build a data package for advancing FXS therapeutics.
  • Patient Organizations (ALS Association, Project ALS, Target ALS, NEALS, I AM ALS, ALS Foundation, and others)minorStrategic or Co-development Partner · 27 June 2023QurAlis maintains partnerships with multiple ALS patient organizations to support clinical trial recruitment, patient engagement, and awareness. These organizations include ALS Association, ALS Foundation, Project ALS, Target ALS, NEALS, I AM ALS, and others. These partnerships facilitate patient-centered drug development and community outreach.
  • Eli Lilly and Company (Kv7.2/7.3 Deal)coreStrategic or Co-development Partner · 1 January 2020QurAlis signed a deal with Eli Lilly in 2020 focused on Kv7.2/7.3 dysfunction in ALS, which built on QurAlis' foundational science showing that Kv7.2/7.3 dysfunction drives toxic hyperexcitability-induced neurodegeneration in ALS. This partnership contributed to the development of QRL-101.

Scale indicators8 records

Recent moves8 records

Expansion highlights7 records

QurAlis competitors and assessment

Company assessment

Direct peers

  • Ionis Pharmaceuticals: Category-defining antisense oligonucleotide therapeutics company and the most direct competitor to QurAlis. Ionis developed Spinraza (nusinersen) for SMA and tofersen for SOD1 ALS, and operates a broad CNS ASO pipeline that directly overlaps with QurAlis' FlexASO platform approach. Its proven track record in ASO development and CNS delivery is the benchmark QurAlis is measured against.
  • Wave Life Sciences: Clinical-stage RNA therapeutics company with a stereopure ASO platform targeting neurological diseases including ALS and Huntington's disease. Wave's PRISM platform overlaps directly with QurAlis' FlexASO chemistry approach, and its CTO Hagen Cramer's prior leadership at Wave makes it a particularly close technology analog.
  • Stoke Therapeutics: Clinical-stage biotechnology company developing antisense oligonucleotide medicines that increase protein expression via RNA splicing modulation for genetic diseases, including CNS disorders such as Dravet syndrome and ADOA. Direct platform analog to QurAlis' FlexASO splice-modulator approach in the rare neurological disease space.
  • Denali Therapeutics: Clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases including ALS, Parkinson's, and Hunter syndrome. Denali is one of the most advanced and well-capitalized private competitors in the neurodegenerative precision-medicine space, directly competing for partnerships and ALS market positioning.

Broad incumbents

  • Biogen: Large biopharmaceutical company commercializing tofersen (with Ionis) for SOD1 ALS and the broader Spinraza SMA franchise. Biogen is the dominant commercial incumbent in ALS therapeutics and represents the standard-of-care competitor QurAlis would face at launch, with far greater commercial infrastructure and reimbursement leverage.
  • Alnylam Pharmaceuticals: Established RNA interference (siRNA) therapeutics leader with multiple approved products and an active CNS pipeline (e.g., for Huntington's disease). Competes with QurAlis in the broader RNA therapeutics space for capital, partnerships, and physician attention, though Alnylam's siRNA modality differs from QurAlis' ASO approach.

Emerging players

  • ProQR Therapeutics: Clinical-stage RNA editing company developing Axiomer® platform-based therapies for genetic diseases including CNS and ophthalmology indications. Overlaps with QurAlis in RNA-targeted therapeutic modalities and rare neurological disease focus, though using an editing rather than splice-modulating mechanism.
  • Karuna Therapeutics: Neuroscience-focused clinical-stage biotech acquired by Bristol-Myers Squibb for $14 billion in 2024 for its schizophrenia therapy. Karuna is a directly relevant precedent for QurAlis' exit trajectory given the shared CFO background (Jason Brown) and the demonstrated large-pharma appetite for CNS-focused clinical-stage biotechs.
  • Sage Therapeutics: Clinical-stage neuroscience company developing CNS therapies (Zulresso, Zurzuvae) with overlapping neuroscience drug development infrastructure and investor base. Comparable in clinical-stage neuroscience focus and indication-overlap (epilepsy is one of QurAlis' expansion areas).
  • Arrowhead Pharmaceuticals: Clinical-stage RNA therapeutics company with multiple modalities including siRNA and ASO-like trigger designs targeting liver and CNS diseases. Comparable as a private/public RNA therapeutics competitor with active neurology pipeline programs and broad platform ambitions similar to QurAlis' FlexASO strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

QurAlis social profiles

Digital presence

QurAlis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

QurAlis leadership team

Management profile

Number of profiles

Profiles11 records

QurAlis funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

QurAlis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QurAlis

What does QurAlis do?

QurAlis is a clinical-stage biotechnology company developing precision antisense oligonucleotide (ASO) medicines that target defined genetic and molecular drivers of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Its wholly owned lead candidates are QRL-201 (first-in-class STATHMIN-2 restoring ASO for sporadic ALS, in Phase 1/2 ANQUR) and QRL-101 (selective Kv7.2/7.3 ion channel opener for ALS and epilepsy, in Phase 1). Its UNC13A asset QRL-204 has been out-licensed to Eli Lilly. All candidates are generated through the proprietary FlexASO® Splice Modulator Platform, which QurAlis also leverages for collaborations such as UMass Chan's Fragile X syndrome program.

Is QurAlis a public or private company?

QurAlis is a private company. It is classified as venture growth investor backed and is currently operating.

When was QurAlis founded?

QurAlis was founded in 2016. It employs 51 to 100 people.

Where is QurAlis based?

QurAlis is headquartered in Cambridge, United States, in the North America region.

How does QurAlis make money?

Two revenue lines are on record. Biopharmaceutical Development and Commercialization is the primary driver. The others are licensing and Milestone Payments.

Who are QurAlis's main competitors?

Direct peers on record are Ionis Pharmaceuticals, Wave Life Sciences, Stoke Therapeutics and Denali Therapeutics. Broad incumbents are Biogen and Alnylam Pharmaceuticals. Emerging players are ProQR Therapeutics, Karuna Therapeutics, Sage Therapeutics and Arrowhead Pharmaceuticals.

Does QurAlis have an API?

No public API is recorded for QurAlis.

What industry is QurAlis in?

QurAlis's product category is ALS and Neurodegenerative Disease Precision Medicine. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageQurAlis Receives FDA Clearance for IND Application of QRL-201 for the Treatment of ALS, Clearing a Path to Initiation of Pivotal Clinical Trial in the U.S.QurAlis received FDA clearance for its IND application for QRL-201, an antisense oligonucleotide for ALS, enabling the pivotal CONQUR trial. The ANQUR trial's DRF phase showed QRL-201 slowed disease progression by 50% (p<0.05) and reduced neurofilament biomarkers. QurAlis plans to start the pivotal trial in the first half of 2027.FinancialContent Business PageArticles from QurAlis CorporationQurAlis Corporation announced the opening of its new 30,000-square-foot global headquarters in Cambridge, Massachusetts. This state-of-the-art facility doubles the company's footprint within the Alewife Biotech Park.BioSpaceQurAlis to Participate in Upcoming Investor Conferences in September 2026QurAlis Corporation announced CEO Kasper Roet will present at investor conferences in September 2026, including Wells Fargo, Morgan Stanley, H.C. Wainwright, World Medical Innovation Forum, and Bank of America. The company also plans one-on-one investor meetings at these events.Neurology liveDosing Begins for Phase 1 Study of Kv7.2/7.3 Ion Channel Opener QRL-101 in ALSQurAlis has commenced dosing for the phase 1 multiple-ascending dose (MAD) clinical trial of QRL-101, a first-in-class Kv7.2/7.3 ion channel opener intended for the treatment of amyotrophic lateral sclerosis (ALS). The study involves 60 healthy participants across up to five cohorts and is expected to report topline results in the first half of 2025. This development follows positive safety data from an earlier single-ascending dose study, positioning QRL-101 as a potential therapy for hyperexcitability-induced neurodegeneration.Neurology liveSTATHMIN-Targeting Therapy QRL-201 Enters Dose Range-Finding Phase Following Successful PK AnalysisQurAlis announced that its investigational therapy QRL-201 has entered the dose range-finding phase of its phase 1 ANQUR clinical trial for ALS after successfully completing dose escalation with cerebrospinal fluid exposure levels meeting therapeutic targets. The upcoming phase will enroll an additional 48 participants, including a new cohort of patients with C9orf72-related ALS, across sites in Canada, the UK, and the EU. This progression supports the company's confidence in QRL-201's potential to modify disease progression by restoring STATHMIN-2 expression.BioSpaceQurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALSQurAlis presented interim Phase 2 data at Target ALS's annual meeting showing its antisense oligonucleotide QRL-201 produced up to a 50% decrease in disease progression among 69 ALS patients, with cerebrospinal fluid reductions in two biomarkers of axonal damage. The biotech also reported at least a doubling of stathmin-2 levels — the most downregulated protein in sporadic ALS — providing what its CEO called the first validation of a genetic medicine having a transformative effect on the disease since Biogen and Ionis won conditional FDA approval for Qalsody in 2023. QurAlis is preparing to launch a Phase 3 trial of QRL-201 in approximately 270 patients in the first quarter of 2027.GenengnewsHopes Raised for More Sustainable Oligonucleotide ManufacturingQurAlis highlights enzymatic synthesis as a more sustainable alternative to traditional solid-phase methods for manufacturing oligonucleotides, aiming to reduce solvent waste and improve mass intensity. However, significant challenges remain regarding enzyme selection, production scalability above 100 grams, and reaction speed compared to existing chemical processes. The company suggests that while clinical-stage firms may continue using current methods, commercial-stage producers are likely to adopt these new approaches post-market launch.openPR.comLou Gehrig's Disease Pipeline Grows as 75+ Pharma Companies Advance Novel ALS Therapies, Finds DelveInsight | Ionis Pharmaceuticals, MediciNova, Revalesio, QurAlis, MediciNovaDelveInsight published a market research report identifying 75+ pharmaceutical companies developing 80+ pipeline therapies for Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease. Multiple companies have recently advanced clinical programs, including Vector Y Therapeutics (Phase 1/2 Vtx-002 study, April 2026), argenx (Phase 2a ARGX-119 study, April 2026), PhenoNet Inc. (Phase IIB PHENOGENE-1A study, April 2026), and AL-S Pharma (positive Phase II AP-101 topline results, September 2025). Key drug candidates in advanced stages include Ionis Pharmaceuticals' Ulefnersen (Phase III), MediciNova's MN-166 (Phase II/III), and Revalesio's RNS60 (Phase II, FDA Fast Track designated).TargetalsQ1 2026 Research SpotlightsTarget ALS highlighted QurAlis' positive interim data from its ANQUR trial for QRL-201, a therapeutic targeting STATHMIN-2 expression in ALS patients. The organization also announced a new three-year precompetitive consortium led by Vlaams Instituut voor Biotechnologie (VIB) to investigate C9orf72-related ALS and FTD mechanisms.In VivoQurAlis In Fundraising Mode After Potentially Value-Creating Readout In ALSQurAlis reported promising Phase I/II results for its ALS drug candidate QRL-201, aiming to validate its precision medicine approach and support a Series C venture capital fundraising round. The company plans to use the proceeds to fund a Phase III clinical trial expected to begin in 2027 and advance other clinical-stage assets.